Sage Therapeutics Company Profile (NASDAQ:SAGE)

About Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SAGE
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.15 billion
  • Outstanding Shares: 37,346,000
Average Prices:
  • 50 Day Moving Avg: $79.56
  • 200 Day Moving Avg: $67.52
  • 52 Week Range: $35.02 - $88.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.05
  • P/E Growth: 5.47
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $8.54 per share
  • Price / Book: 9.87
  • EBIDTA: ($186,560,000.00)
  • Return on Equity: -54.56%
  • Return on Assets: -50.48%
  • Current Ratio: 10.95%
  • Quick Ratio: 10.95%
  • Average Volume: 375,473 shs.
  • Beta: 2.96
  • Short Ratio: 10.91
Frequently Asked Questions for Sage Therapeutics (NASDAQ:SAGE)

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $0.09. View Sage Therapeutics' Earnings History.

Where is Sage Therapeutics' stock going? Where will Sage Therapeutics' stock price be in 2017?

11 equities research analysts have issued 12-month price objectives for Sage Therapeutics' stock. Their forecasts range from $60.00 to $110.00. On average, they expect Sage Therapeutics' share price to reach $85.82 in the next twelve months. View Analyst Ratings for Sage Therapeutics.

What are analysts saying about Sage Therapeutics stock?

Here are some recent quotes from research analysts about Sage Therapeutics stock:

  • 1. Needham & Company LLC analysts commented, "We hosted a call with expert Dr. Peter Kaplan to review the super refractory status epilepticus (SRSE) space and expectations for Sage Therapeutics’ drug IV brexanolone, which is currently being evaluated in the ongoing pivotal Phase 3 STATUS trial (results expected 3Q17). Dr. Kaplan has been practicing at Johns Hopkins for 30 years and his academic experience has been mostly clinical in nature. He is currently based at Johns Hopkins Bayview Medical Center and is consulted throughout the hospital for input regarding EEGs and for optimal management of status epilepticus. Below we highlight our key takeaways from the call." (6/13/2017)
  • 2. BMO Capital Markets analysts commented, "We spoke with two leading psychiatrists who agreed that these data, while early, look great; they were particularly impressed with the magnitude of effect, early onset, strong remission rate, and overall safety for SAGE-217 in MDD. This profile is considered the 'holy grail' in treating depression. The physicians were also very optimistic regarding the prospects for SAGE-217 in a placebo-controlled trial for MDD given the large effect size in the open-label (one said 75-80% chance of success)' We are now including risk-adjusted sales for SAGE-217 in MDD of $25mn in 2021 ramping up to $325mn in 2027. We partially offset that with some increased expenses; the net result was that our EPS changed by $(0.51)-4.04 in 2017-27, and our target goes to $82 from $68." (2/22/2017)
  • 3. Chardan Capital analysts commented, "Yesterday, Sage Therapeutics announced encouraging top-line phase II results from its open label clinical trial of orally-administered SAGE-217 for major depressive disorder (MDD). Our discussions yesterday with industry participants in the depression space suggested a decidedly positive view of the SAGE-217 data. We now note that the SAGE-217 result follows what to us, in our 12 July 2016 research, was "potentially clear, positive" phase II data for IV SAGE-547 in severe postpartum depression (PPD). Although our 20 July 2016 questions on SAGE-547 remain unanswered, we are reassured by the granting of Breakthrough Therapy Designation (BTD) for SAGE-547 by the FDA and PRIME Designation by EMA, which both likely independently considered the issues we raised. Our initial 24 May 2016 bearish view on Sage was based largely on our expectations of phase III data for SAGE-547 in super-refractory status epilepticus (SRSE), which were originally due to read out in 2H16. The timing of the data has since moved to 1H17, exposing any SAGE-547 SRSE bear thesis to the upside potential surrounding SAGE-217 in MDD, and more limited potential of SAGE-547 in PPD. Indeed, we now see upside risk elsewhere in Sage and thereby upgrade from Sell to Neutral, raising our PT from $18 to $60." (2/14/2017)
  • 4. Cowen and Company analysts commented, "Today SAGE announced positive top-line results from its Ph2 OL trial of SAGE-217 in." (2/13/2017)
  • 5. Canaccord Genuity analysts commented, "We are encouraged by NDRM’s progress on its multiple development programs and continue to view the company’s approach to treating Parkinson’s disease as potentially paradigm-shifting. NDRM recently had an end of Ph2 meeting with the FDA to discuss ND0612 and has been allowed to move forward with PK equivalency in the US as opposed to doing a Ph3 efficacy trial. Additionally, NDRM announced positive top-line data from a pilot PK trial of ND0701 last week." (12/6/2016)

Who are some of Sage Therapeutics' key competitors?

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the folowing people:

  • Kevin P. Starr, Independent Chairman of the Board
  • Jeffrey M. Jonas M.D., President, Chief Executive Officer, Director
  • Kimi E. Iguchi, Chief Financial Officer, Treasurer
  • Anne Marie Cook, Senior Vice President, General Counsel
  • Amy Schacterle Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Christopher Silber, Senior Vice President - Clinical Development
  • Albert J. Robichaud Ph.D., Chief Scientific Officer
  • Frank Sanders, Vice President of Sales and Marketing
  • Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration
  • Thomas D. Anderson, Chief Commercial Strategy Officer

Who owns Sage Therapeutics stock?

Sage Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.06%), Handelsbanken Fonder AB (0.04%), First Midwest Bank Trust Division (0.01%), Fox Run Management L.L.C. (0.01%) and Dubuque Bank & Trust Co. (0.01%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for Sage Therapeutics.

Who sold Sage Therapeutics stock? Who is selling Sage Therapeutics stock?

Sage Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB. View Insider Buying and Selling for Sage Therapeutics.

Who bought Sage Therapeutics stock? Who is buying Sage Therapeutics stock?

Sage Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Russell Investments Group Ltd., Fox Run Management L.L.C. and Dubuque Bank & Trust Co.. View Insider Buying and Selling for Sage Therapeutics.

How do I buy Sage Therapeutics stock?

Shares of Sage Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sage Therapeutics' stock price today?

One share of Sage Therapeutics stock can currently be purchased for approximately $84.27.

MarketBeat Community Rating for Sage Therapeutics (NASDAQ SAGE)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Sage Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $85.82 (1.84% upside)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Stifel NicolausReiterated RatingBuy$90.00MediumView Rating Details
6/20/2017Leerink SwannReiterated RatingOutperform$90.00 -> $97.00HighView Rating Details
6/13/2017Needham & Company LLCReiterated RatingBuy$82.00MediumView Rating Details
6/12/2017Cowen and CompanyInitiated CoverageOutperform$95.00LowView Rating Details
5/12/2017Bank of America CorporationInitiated CoverageBuy -> Buy$85.00HighView Rating Details
5/10/2017Canaccord GenuityReiterated RatingBuy$110.00MediumView Rating Details
4/3/2017J P Morgan Chase & CoReiterated RatingBuy$83.00HighView Rating Details
2/22/2017HC WainwrightDowngradeBuy -> Neutral$56.00 -> $76.00N/AView Rating Details
2/22/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 -> $82.00N/AView Rating Details
2/14/2017Chardan CapitalUpgradeSell -> Neutral$60.00N/AView Rating Details
12/14/2016Raymond James Financial, Inc.UpgradeOutperform -> Strong-Buy$84.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
4/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$63.00N/AView Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Sage Therapeutics (NASDAQ:SAGE)
Earnings by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Earnings History by Quarter for Sage Therapeutics (NASDAQ SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($1.61)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
2017 EPS Consensus Estimate: ($6.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.58)($1.49)($1.54)
Q2 20173($1.64)($1.50)($1.56)
Q3 20173($1.70)($1.43)($1.58)
Q4 20173($1.70)($1.45)($1.56)
(Data provided by Zacks Investment Research)


Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sage Therapeutics (NASDAQ:SAGE)
Insider Ownership Percentage: 6.10%
Insider Trades by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Insider Trades by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.00View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.00View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.00View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sage Therapeutics (NASDAQ:SAGE)
Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
DateHeadline logoSage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017 - July 22 at 8:31 AM logoSage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017 - Business Wire (press release) - July 21 at 6:52 AM logo-$1.66 Earnings Per Share Expected for Sage Therapeutics, Inc. (SAGE) This Quarter - July 19 at 8:54 AM logoStifel Nicolaus Reaffirms Buy Rating for Sage Therapeutics, Inc. (NASDAQ:SAGE) - July 15 at 7:27 AM logoSage Therapeutics Spicing Up Portfolios - Seeking Alpha - July 8 at 2:12 PM logoSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Recommendation of "Buy" from Brokerages - July 3 at 9:56 AM logoSage Therapeutics, Inc. (SAGE) Downgraded by BidaskClub to Buy - June 28 at 4:56 PM logo Brokerages Anticipate Sage Therapeutics, Inc. (SAGE) to Post -$1.64 EPS - June 23 at 12:14 AM logoLeerink Swann Comments on Sage Therapeutics, Inc.'s FY2019 Earnings (SAGE) - June 22 at 2:32 PM logoSage Therapeutics' (SAGE) "Outperform" Rating Reaffirmed at Leerink Swann - June 20 at 11:08 AM logoNeedham & Company LLC Reaffirms "Buy" Rating for Sage Therapeutics, Inc. (SAGE) - June 18 at 3:38 PM logoCompany Spotlight: SAGE Therapeutics - June 17 at 1:56 AM logoUNC working with Mass. pharma company on depression drug - June 15 at 12:20 AM logoBidaskClub Upgrades Sage Therapeutics, Inc. (SAGE) to "Strong-Buy" - June 13 at 8:32 PM logoSage Therapeutics (SAGE) and Celgene Corporation (CELG) Financial Analysis - June 13 at 8:15 PM logoBRIEF-Sage Therapeutics announces the lancet publishes positive phase 2 brexanolone (sage-547) clinical data - June 13 at 9:58 AM logoSage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression - June 13 at 9:58 AM logoSage Therapeutics, Inc. (SAGE) Now Covered by Cowen and Company - June 12 at 9:16 AM logoCowen Starts Sage Therapeutics (SAGE ) at Outperform, Top SMIDcap Pick - - June 12 at 8:07 AM logoSage Therapeutics to Present at Goldman Sachs Healthcare Conference - June 8 at 9:45 PM logoSAGE Therapeutics Inc (SAGE) Receives Average Rating of "Buy" from Analysts - June 6 at 9:02 AM logoSage Therapeutics Announces Inducement Grants Under NASDAQ ... - Business Wire (press release) - June 5 at 8:31 PM logoSAGE Therapeutics Inc (SAGE) Upgraded to Hold at ValuEngine - June 3 at 11:32 AM logo Analysts Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$1.63 Per Share - May 29 at 8:44 PM logoSage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder - May 18 at 11:35 AM logoBiotech Movers: Fast Track Designation Sends Sage Shares Higher - May 18 at 11:35 AM logoBioverativ Inc. (BIVV) Appoints Geno Germano to Board of Directors - May 15 at 6:53 PM logoBioverativ Appoints Geno J. Germano to Company’s Board of Directors - May 15 at 6:53 PM logoSAGE Therapeutics Inc (SAGE) Coverage Initiated by Analysts at Needham & Company LLC - May 15 at 5:42 PM logoSAGE Therapeutics Inc (SAGE) Coverage Initiated by Analysts at Bank of America Corp - May 13 at 12:32 AM logoSAGE Therapeutics Inc (SAGE) Given Consensus Rating of "Buy" by Analysts - May 12 at 9:52 AM logoSAGE Therapeutics Inc (SAGE) Expected to Post Q2 2017 Earnings of ($1.50) Per Share - May 12 at 8:35 AM logoQ2 2017 EPS Estimates for SAGE Therapeutics Inc (SAGE) Raised by William Blair - May 12 at 8:34 AM logoQ2 2017 Earnings Forecast for SAGE Therapeutics Inc Issued By Leerink Swann (SAGE) - May 12 at 8:34 AM logoFY2020 EPS Estimates for SAGE Therapeutics Inc Increased by Analyst (SAGE) - May 11 at 3:40 PM logoSAGE Therapeutics Inc (SAGE) Releases Quarterly Earnings Results - May 10 at 6:40 PM logoSage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update - Business Wire (press release) - May 10 at 11:04 AM logoSAGE Therapeutics' (SAGE) Buy Rating Reaffirmed at Canaccord Genuity - May 10 at 7:36 AM logoBRIEF-Sage Therapeutics qtrly loss per share $1.52 - May 9 at 7:11 PM logoSage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update - May 9 at 7:11 PM logoSage Therapeutics reports 1Q loss - May 9 at 4:19 PM logoSAGE Therapeutics (SAGE) Earns Daily Media Sentiment Score of 0.07 - May 5 at 11:45 PM logoSAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.56 Per Share - May 4 at 8:14 AM logoSAGE Therapeutics (SAGE) Getting Somewhat Favorable Press Coverage, Study Finds - May 3 at 1:03 AM logoSage Therapeutics Announces Initiation of Phase 1 Development ... - Business Wire (press release) - April 27 at 8:07 PM logoBRIEF-Sage Therapeutics initiates phase 1 single ascending dose trial - Reuters - April 27 at 8:07 PM logoSage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718 - April 27 at 8:07 PM logoSage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 - Business Wire (press release) - April 26 at 8:59 PM logoSAGE Therapeutics (SAGE) Receives Media Impact Rating of 0.47 - April 26 at 4:04 PM logoCramer's lightning round: Buy, buy, buy this high-flying bank stock - April 26 at 3:57 PM



Sage Therapeutics (SAGE) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff